Daniela Pende

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7930552/publications.pdf

Version: 2024-02-01

152 papers	17,891 citations	14653 66 h-index	12944 131 g-index
154 all docs	154 docs citations	154 times ranked	13432 citing authors

#	Article	IF	Citations
1	Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis. Annual Review of Immunology, 2001, 19, 197-223.	21.8	1,609
2	RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS. Annual Review of Immunology, 1996, 14, 619-648.	21.8	833
3	Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule. Journal of Experimental Medicine, 2003, 198, 557-567.	8.5	779
4	Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells. Journal of Experimental Medicine, 1999, 190, 1505-1516.	8.5	664
5	Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.. Blood, 2007, 110, 433-440.	1.4	550
6	Defective expression and function of natural killer cellâ€“triggering receptors in patients with acute myeloid leukemia. Blood, 2002, 99, 3661-3667.	1.4	434
7	Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Research, 2002, 62, 6178-86.	0.9	396
8	NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. European Journal of Immunology, 1999, 29, 1656-1666.	2.9	392
9	HLA-haploidentical stem cell transplantation after removal of Î±Î²+ T and B cells in children with nonmalignant disorders. Blood, 2014, 124, 822-826.	1.4	385
10	NK-dependent DC maturation is mediated by TNFÎ± and IFNÎ³ released upon engagement of the NKp30 triggering receptor. Blood, 2005, 106, 566-571.	1.4	365
11	Analysis of the receptor-ligand interactions in the natural killerâ€“mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	1.4	344
12	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	1.4	343
13	Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunological Reviews, 1997, 155, 105-117.	6.0	333
14	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. Journal of Clinical Investigation, 2009, 119, 1251-1263.	8.2	313
15	Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. European Journal of Immunology, 2001, 31, 1076-1086.	2.9	299
16	HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood, 2005, 105, 251-258.	1.4	291
17	Human natural killer cell receptors and coâ€receptors. Immunological Reviews, 2001, 181, 203-214.	6.0	273
18	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179.	4.8	269

#	Article	IF	Citations
19	A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood, 2012, 119, 2754-2763.	1.4	263
20	Effector and regulatory events during natural killer?dendritic cell interactions. Immunological Reviews, 2006, 214, 219-228.	6.0	261
21	Outcome of children with acute leukemia given HLA-haploidentical HSCT after Î±Î² T-cell and B-cell depletion. Blood, 2017, 130, 677-685.	1.4	261
22	Surface NK receptors and their ligands on tumor cells. Seminars in Immunology, 2006, 18, 151-158.	5.6	247
23	Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood, 2006, 107, 2030-2036.	1.4	234
24	Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood, 2007, 109, 3776-3785.	1.4	227
25	Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells. Cancer Research, 2004, 64, 9180-9184.	0.9	224
26	Î³Î´ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-Î±Î²+/CD19+ lymphocytes. Blood, 2015, 125, 2349-2358.	1.4	224
27	Killer Igâ€“like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood, 2011, 117, 764-771.	1.4	218
28	Human natural killer cells: their origin, receptors and function. European Journal of Immunology, 2002, 32, 1205.	2.9	217
29	Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma. Neoplasia, 2004, 6, 558-568.	5.3	216
30	Pathogenesis of haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2001, 114, 761-769.	2.5	189
31	Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood, 2011, 118, 3301-3310.	1.4	188
32	Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. Journal of Experimental Medicine, 2006, 203, 2339-2350.	8.5	162
33	Analysis of natural killerâ€“cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood, 2006, 108, 2316-2323.	1.4	161
34	p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. European Journal of Immunology, 1998, 28, 1980-1990.	2.9	144
35	Different checkpoints in human NK-cell activation. Trends in Immunology, 2004, 25, 670-676.	6.8	140
36	Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. Journal of Allergy and Clinical Immunology, 2016, 137, 188-196.e4.	2.9	139

#	Article	IF	Citations
37	Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. European Journal of Immunology, 1999, 29, 3148-3159.	2.9	135
38	NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 2021, 80, 100870.	6.4	134
39	The murine homologue of the human NKp46, a triggering receptor involved in the induction of natural cytotoxicity. European Journal of Immunology, 1999, 29, 1014-1020.	2.9	133
40	A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. European Journal of Immunology, 1996, 26, 1816-1824.	2.9	126
41	PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Molecular Immunology, 2005, 42, 463-469.	2.2	120
42	NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. Trends in Immunology, 2018, 39, 577-590.	6.8	119
43	Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vî³9/Vî´2 T cells in tumor immunity. European Journal of Immunology, 1997, 27, 3368-3379.	2.9	115
44	NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. European Journal of Immunology, 2001, 31, 1656-1665.	2.9	115
45	Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunology Letters, 2005, 100, 7-13.	2.5	113
46	Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B - Clinical Cytometry, 2017, 92, 100-114.	1.5	110
47	NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood, 2011, 117, 848-856.	1.4	108
48	Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. Journal of Neuroimmunology, 2000, 107, 220-225.	2.3	103
49	Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. European Journal of Immunology, 2006, 36, 3198-3206.	2.9	99
50	Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Frontiers in Immunology, 2013, 4, 15.	4.8	98
51	The activating form of CD94 receptor complex: CD94 covalently associated with the Kp39 protein that represents the product of the NKG2-C gene. European Journal of Immunology, 1998, 28, 327-338.	2.9	94
52	Familial Hemophagocytic Lymphohistiocytosis: When Rare Diseases Shed Light on Immune System Functioning. Frontiers in Immunology, 2014, 5, 167.	4.8	93
53	Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells. European Journal of Immunology, 1994, 24, 1003-1006.	2.9	91
54	The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR Î±/Î²-mediated recognition. European Journal of Immunology, 2001, 31, 3687-3693.	2.9	91

#	Article	IF	Citations
55	Effect Of Human Natural Killer and Î³Î´ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice. Cancer Research, 2004, 64, 378-385.	0.9	90
56	Lysis of Endogenously Infected CD4+ T Cell Blasts by rIL-2 Activated Autologous Natural Killer Cells from HIV-Infected Viremic Individuals. PLoS Pathogens, 2008, 4, e1000101.	4.7	88
57	HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. European Journal of Immunology, 1997, 27, 1875-1880.	2.9	84
58	Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood, 2009, 114, 4108-4116.	1.4	84
59	CD3+4â^'8â^'WT31â^' (T cell receptor Î³+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. European Journal of Immunology, 1987, 17, 1815-1819.	2.9	81
60	A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood, 2005, 106, 932-937.	1.4	80
61	Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing ÂÂ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica, 2016, 101, 371-381.	3.5	80
62	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Frontiers in Immunology, 2014, 5, 87.	4.8	77
63	Familial Hemophagocytic Lymphohistiocytosis May Present during Adulthood: Clinical and Genetic Features of a Small Series. PLoS ONE, 2012, 7, e44649.	2.5	77
64	Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clinical Immunology, 2009, 133, 171-178.	3.2	76
65	Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. Journal of Medical Genetics, 2011, 48, 343-352.	3.2	76
66	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. Clinical Cancer Research, 2018, 24, 870-881.	7.0	75
67	Human NK cells, their receptors and function. European Journal of Immunology, 2021, 51, 1566-1579.	2.9	75
68	Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica, 2010, 95, 538-541.	3.5	70
69	Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Molecular Immunology, 2004, 41, 569-575.	2.2	68
70	Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Letters, 2008, 272, 110-121.	7.2	65
71	Human NK cells and their receptors. Microbes and Infection, 2002, 4, 1539-1544.	1.9	64
72	Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing. Cancer Research, 2011, 71, 1597-1606.	0.9	64

#	Article	IF	Citations
73	Centriole polarisation to the immunological synapse directs secretion from cytolytic cells of both the innate and adaptive immune systems. BMC Biology, 2011, 9, 45.	3.8	60
74	NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. European Journal of Immunology, 2003, 33, 2033-2043.	2.9	59
75	Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression. British Journal of Haematology, 2002, 119, 180-188.	2.5	58
76	The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. European Journal of Immunology, 1998, 28, 2384-2394.	2.9	57
77	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. Frontiers in Immunology, 2019, 10, 1415.	4.8	57
78	Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood, 2010, 115, 5170-5179.	1.4	56
79	Modulation of CD112 by the alphaherpesvirus gD protein suppresses DNAM-1â€“dependent NK cell-mediated lysis of infected cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16118-16123.	7.1	55
80	NK Cell-Based Immunotherapy for Hematological Malignancies. Journal of Clinical Medicine, 2019, 8, 1702.	2.4	54
81	CD 16 surface molecules regulate the cytolytic function of CD3â˜CD16+ human natural killer cells. International Journal of Cancer, 1989, 44, 727-730.	5.1	52
82	ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors. Cancer Research, 2015, 75, 824-834.	0.9	52
83	Inhibitory Receptor Signals Suppress Ligation-Induced Recruitment of NKG2D to GM1-Rich Membrane Domains at the Human NK Cell Immune Synapse. Journal of Immunology, 2007, 178, 5606-5611.	0.8	51
84	Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2156.	4.8	49
85	STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. Journal of Medical Genetics, 2010, 47, 595-600.	3.2	48
86	Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96. Cancer Research, 2005, 65, 3942-3949.	0.9	47
87	Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. Aids, 2001, 15, 965-974.	2.2	44
88	Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients. Journal of Immunotherapy, 2016, 39, 90-100.	2.4	44
89	Specificity of human T lymphocytes expressing a Î³/Î´ T cell antigen receptor. Recognition of a polymorphic determinant of HLA class I molecules by a Î³/Î´ clone. European Journal of Immunology, 1989, 19, 1267-1271.	2.9	42
90	Familial hemophagocytic lymphohistiocytosis: a model for understanding the human machinery of cellular cytotoxicity. Cellular and Molecular Life Sciences, 2012, 69, 29-40.	5.4	40

#	Article	IF	Citations
91	Patients with Griscelli syndrome and normal pigmentation identify RAB27A mutations that selectively disrupt MUNC13-4 binding. Journal of Allergy and Clinical Immunology, 2015, 135, 1310-1318.e1.	2.9	40
92	Human natural killer cell activating receptors. Molecular Immunology, 2000, 37, 1015-1024.	2.2	36
93	Human NK receptors: From the molecules to the therapy of high risk leukemias. FEBS Letters, 2011, 585, 1563-1567.	2.8	36
94	Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. PLoS ONE, 2009, 4, e8132.	2.5	36
95	The molecular basis of Natural Killer (NK) cell recognition and function. Journal of Clinical Immunology, 1996, 16, 243-253.	3.8	35
96	Human NK cells: From surface receptors to clinical applications. Immunology Letters, 2016, 178, 15-19.	2.5	35
97	The Activating Human NK Cell Receptor KIR2DS2 Recognizes a Î²2-Microglobulinâ€“Independent Ligand on Cancer Cells. Journal of Immunology, 2017, 198, 2556-2567.	0.8	35
98	Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies. Frontiers in Immunology, 2019, 10, 1876.	4.8	35
99	Human CD3+4â^'8â^'WT31â^'T lymphocyte expressing the putative T cell receptor Î³-gene product. A limiting dilution and clonal analysis. European Journal of Immunology, 1987, 17, 1229-1234.	2.9	34
100	Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3. Haematologica, 2008, 93, 1086-1090.	3.5	34
101	Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. OncoImmunology, 2015, 4, e1052353.	4.6	34
102	Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunology, Immunotherapy, 2016, 65, 465-476.	4.2	34
103	Natural killer cells in lymph nodes of healthy calves express CD16 and show both cytotoxic and cytokine-producing properties. Developmental and Comparative Immunology, 2008, 32, 773-783.	2.3	32
104	Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining. Journal of Immunology, 2010, 185, 433-441.	0.8	32
105	Neuroradiologic findings and followâ€up with magnetic resonance imaging of the genetic forms of haemophagocytic lymphohistiocytosis with CNS involvement. Pediatric Blood and Cancer, 2012, 58, 810-814.	1.5	32
106	General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect. International Immunology, 1995, 7, 393-400.	4.0	31
107	Direct involvement of CD56 in cytokine-induced killerâ€“mediated lysis of CD56+ hematopoietic target cells. Experimental Hematology, 2014, 42, 1013-1021.e1.	0.4	31
108	NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients. Clinical Cancer Research, 2007, 13, 7459-7468.	7.0	26

#	Article	IF	Citations
109	T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells. European Journal of Immunology, 1986, 16, 1623-1625.	2.9	25
110	Cellular and molecular basis of natural killer and natural killer-like activity. Immunology Letters, 2003, 88, 89-93.	2.5	25
111	Identification of CD300a as a new hypoxia-inducible gene and a regulator of CCL20 and VEGF production by human monocytes and macrophages. Innate Immunity, 2014, 20, 721-734.	2.4	23
112	TCRÎ±Î²/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. Blood Advances, 2022, 6, 281-292.	5.2	22
113	Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1. European Journal of Immunology, 2016, 46, 1511-1517.	2.9	21
114	Variations of the UNC13D Gene in Patients with Autoimmune Lymphoproliferative Syndrome. PLoS ONE, 2013, 8, e68045.	2.5	20
115	<scp>XLP</scp>1 inhibitory effect by 2<scp>B</scp>4 does not affect <scp>DNAM</scp>â€1 and <scp>NKG</scp>2<scp>D</scp> activating pathways in <scp>NK</scp> cells. European Journal of Immunology, 2014, 44, 1526-1534.	2.9	20
116	Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1. Journal of Immunology, 2018, 201, 2028-2041.	0.8	20
117	Phenotypic and Functional Characterization of NK Cells in Î±Î²T-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. Cancers, 2020, 12, 2187.	3.7	19
118	Ovine CD16⁺/CD14⁻blood lymphocytes present all the major characteristics of natural killer cells. Veterinary Research, 2010, 41, 04.	3.0	19
119	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Immunology Research, 2022, 10, 291-302.	3.4	17
120	Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2. International Immunology, 2004, 16, 1459-1466.	4.0	15
121	Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Experimental Hematology, 2009, 37, 1167-1175.	0.4	15
122	Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients. European Journal of Immunology, 2017, 47, 1051-1061.	2.9	15
123	Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. Journal of Allergy and Clinical Immunology, 2014, 134, 1381-1387.e7.	2.9	14
124	Natural killer cells: From surface receptors to the cure of highâ€risk leukemia (Ceppellini Lecture). Hla, 2019, 93, 185-194.	0.6	11
125	2B4 dysfunction in XLP1 NK cells: More than inability to control EBV infection. Clinical Immunology, 2019, 204, 31-36.	3.2	11
126	Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules. Blood Advances, 2020, 4, 2297-2307.	5.2	11

#	Article	IF	Citations
127	Inhibitory and Activatory Receptors for HLA Class I Molecules in Human Natural Killer Cells. Chemical Immunology and Allergy, 1996, 64, 77-87.	1.7	7
128	CD8+ T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. Cancer Immunology, Immunotherapy, 2007, 56, 1065-1076.	4.2	7
129	Analysis of KIR3DP1 Polymorphism Provides Relevant Information on Centromeric KIR Gene Content. Journal of Immunology, 2018, 201, 1460-1467.	0.8	7
130	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15. Cancers, 2019, 11, 1029.	3.7	7
131	Dendritic cell recognition by group 3 innate lymphoid cells through DNAX accessory molecule 1 triggers proinflammatory reciprocal cell activation. Journal of Allergy and Clinical Immunology, 2019, 144, 1118-1122.e6.	2.9	6
132	ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function. Frontiers in Immunology, 2021, 12, 778103.	4.8	6
133	Transplantation of T-Cell Depleted Peripheral Blood Haematopoietic Stem Cells from an HLA-Disparate Family Donor for Children with Hematological Malignancies.. Blood, 2007, 110, 3071-3071.	1.4	5
134	Characterization of <scp>KIR</scp> ⁺ <scp>NK</scp> cell subsets with a monoclonal antibody selectively recognizing <scp>KIR2DL1</scp> and blocking the specific interaction with <scp>HLAâ€</scp>. Hla, 2022, , .	0.6	5
135	Inhibitory and Activatory Receptors for HLA Class I Molecules in Human Natural Killer Cells. Chemical Immunology and Allergy, 1996, 64, 77-87.	1.7	4
136	Removal Of Alpha/Beta+ T Cells and Of CD19+ B Cells From The Graft Translates Into Rapid Engraftment, Absence Of Visceral Graft-Versus-Host Disease and Low Transplant-Related Mortality In Children With Acute Leukemia Given HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 157-157.	1.4	4
137	N-803: a double-edged sword in haplo-NK therapy. Blood, 2022, 139, 1122-1124.	1.4	4
138	Epitope characterization of a monoclonal antibody that selectively recognizes <scp>KIR2DL1</scp> allotypes. Hla, 2022, , .	0.6	3
139	In vitro enhancement of the proliferative response of human T cells to autologous non-T cells by hydralazine. Immunopharmacology, 1986, 11, 183-187.	2.0	2
140	Anti-Leukemia Activity of Alloreactive NK Cells in Haploidentical HSCT in Pediatric Patients: Re-Defining the Role of Activating and Inhibitory KIR. Blood, 2008, 112, 3002-3002.	1.4	2
141	Specificity of Human T Lymphocytes Expressing a Î³/Î´T Cell Antigen Receptor. Recognition of a Polymorphic Determinant of HLA Class I Molecules by a Î³/Î´+ Clone. Current Topics in Microbiology and Immunology, 1991, 173, 223-227.	1.1	2
142	Role of normal adherent cells in the regulation of the autologous mixed lymphocyte reactions in humans. Journal of Clinical Immunology, 1984, 4, 197-201.	3.8	1
143	The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions. International Journal of Immunopharmacology, 1986, 8, 385-390.	1.1	1
144	Glycoproteic nature of surface molecules of effector cells with lymphokine-activated killer (LAK) activity. Evidence that T11, T8 or T3 molecules are not involved in tumor-cell lysis by LAK effector T cells. International Journal of Cancer, 1987, 39, 703-707.	5.1	1

#	Article	IF	Citations
145	Natural Killer (NK) Alloreactivity Seems Not to Play a Role in Preventing Leukemia Relapse in Unmanipulated Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide. Blood, 2015, 126, 2033-2033.	1.4	1
146	Existence of a natural killer (NK) cell repertoire for (allo)antigen recognition: Definition of five distinct NK-determined allospecificities in humans. Pharmacological Research, 1992, 26, 98-99.	7.1	0
147	Defective CD107a Surface Expression Heralds Munc13-4 Defect and Discriminates Between Genetic Subtypes of Familial Hemophagocytic Lymphohistiocytosis (FHL). Clinical Immunology, 2007, 123, S41.	3.2	0
148	OR.69. Alloreactive NK Cells Exert Anti-leukemia Activity in Haplo-HSCT to Pediatric Patients: Revised Role of Activating and Inhibitory KIR. Clinical Immunology, 2009, 131, S29.	3.2	0
149	Novel Munc13-4 Mutations in Patients with Hemophagocytic Lymphohistiocytosis.. Blood, 2005, 106, 2807-2807.	1.4	0
150	Defective CD107a Surface Expression Heralds Munc13-4 Defect and Discriminates between Genetic Subtypes of Familial Hemophagocytic Lymphohistiocytosis (FHL).. Blood, 2006, 108, 1248-1248.	1.4	0
151	MUNC13â€“4 Mutations in Patients with Hemophagocytic Lymphohistiocytosis Are Scattered over the Functional Domains of the Protein.. Blood, 2006, 108, 1249-1249.	1.4	0
152	Heterogeneity of B cell growth factor (BCGF)-producing T cells in humans. Clonal analysis of BCGF-producing cells within T4+ and T8+ subsets and evidence for the involvement of different growth factors in different BCGF assays. Research in Clinic and Laboratory, 1986, 16, 23-28.	0.3	0